<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287949</url>
  </required_header>
  <id_info>
    <org_study_id>RPV04C</org_study_id>
    <nct_id>NCT01287949</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older</brief_title>
  <official_title>An Open-label, Multicentre Study to Evaluate the Immunogenicity and Safety of One Dose of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older Without a Previous Diphtheria- and Tetanus-containing Booster Within the Last 20 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To demonstrate that 3 doses of a vaccine containing Td-IPV valences administered in a 0,
           1 and 6-month schedule induce an acceptable immune response in terms of seroprotection
           rates (SPR) against diphtheria, tetanus and poliomyelitis 1, 2 and 3, in subjects of 40
           years of age or older with no diphtheria- and tetanus-containing booster within the last
           20 years

        -  To evaluate the percentage of subjects with antibody titre ≥5 EU/mL (ELISA) for each of
           the pertussis components (PT, FHA, PRN and FIM) after 1 dose of REPEVAX in these
           subjects

      Secondary objectives:

        -  If the primary objective is achieved, to determine whether 1 or 2 doses of a vaccine
           containing Td-IPV valences induce an acceptable response in terms of seroprotection
           rates (SPR) against diphtheria, tetanus and poliomyelitis 1, 2 and 3, in subjects of 40
           years of age or older with no diphtheria- and tetanus-containing booster within the last
           20 years

        -  To describe the immune responses to REPEVAX in these subjects

        -  To describe the immune responses to REVAXIS administered 1 and 6 months after the
           administration of REPEVAX in these subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diphtheria seroprotection rate</measure>
    <time_frame>28 to 35 days afeter each vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tetanus seroprotection rate</measure>
    <time_frame>28 to 35 days after each vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Polio seroprotection rate</measure>
    <time_frame>28 to 35 days after each vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pertussis response rate</measure>
    <time_frame>28 to 35 days after REPEVAX administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site reactions, solicited systemic reactions</measure>
    <time_frame>From day 0 to day 7 following REPEVAX and REVAXIS vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site adverse reactions and systemic adverse events</measure>
    <time_frame>From day 0 to day 28 following REPEVAX and REVAXIS vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of Serious adverse events</measure>
    <time_frame>From the first vaccination to the last visit of the subject</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Poliomyelitis</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>REPEVAX followed by REVAXIS administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria, tetanus, polio and pertussis vaccination</intervention_name>
    <description>1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later</description>
    <arm_group_label>REPEVAX followed by REVAXIS administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥40 years

          -  No receipt of a booster dose with a tetanus-, diphtheria-containing vaccine within the
             last 20 years

        Exclusion Criteria:

          -  Medically diagnosed pertussis disease within the last 10 years

          -  Receipt of medication / vaccine that may interfere with study assessments

          -  Febrile illness or moderate or severe acute illness/infection

          -  Know pregnancy

          -  History of hypersensitivity or anaphylactic or other allergic reactions to any of the
             vaccine components, or history of a life-threatening reaction to the study vaccines or
             a vaccine containing any of the same substances

          -  History of Guillain Barré syndrome or brachial neuritis following a previous
             vaccination

          -  History of encephalopathy of unknown origin within 7 days after immunization with a
             pertussis-containing vaccine or neurological disorders

          -  Known or suspected immune dysfunction

          -  Thrombocytopenia, bleeding disorder or anticoagulants contraindicating intramuscular
             vaccination

          -  Chronic disease or intercurrent illness that might interfere with study assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Balve</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Dülmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD investigational site</name>
      <address>
        <city>Rodgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Pertussis (acellular)</keyword>
  <keyword>Biological/vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

